In adults with migraine and previous preventive treatment failures, a single infusion of a monoclonal antibody to pituitary adenylate cyclase–activating polypeptide led to fewer migraine days per month than placebo over the next 4 weeks.
The New England Journal of Medicine: Search Results in Endocrinology
